Search Result
Results for "
DSPE-PEG2000-Mal
" in MedChemExpress (MCE) Product Catalog:
13
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-144004
-
|
DSPE-PEG2000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[Maleimide(polyethylene glycol)-2000] ammonium
|
Liposome
|
Others
|
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
-
- HY-172279A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-TAT is a cell-penetrating peptide-modified PEGylated phospholipid conjugate and cellular uptake enhancer. DSPE-PEG2000-TAT forms via conjugation of Cys-TAT to DSPE-PEG2000-Mal. DSPE-PEG2000-TAT enhances liposomal cellular uptake and siRNA transfection efficiency in glomerular mesangial and macrophage cells. DSPE-PEG2000-TAT can be used for drug delivery .
|
-
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
-
- HY-172699
-
|
|
Liposome
LDLR
|
Cancer
|
|
DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .
|
-
-
- HY-172273A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
|
-
-
- HY-172500
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG2000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.
|
-
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
-
- HY-179677
-
|
|
Liposome
|
Others
|
|
DSPE-PEG2000-Mal-Cys-DT7 is a phospholipid-PEG conjugate. DSPE-PEG2000-Mal-Cys-DT7 utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles.
|
-
-
- HY-172497
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
-
-
- HY-172276A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
-
- HY-186176
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DSPE-PEG2000-Mal-Cys-penetratin is a conjugate composed of DSPE, a PEG chain, and terminal maleimide (Mal). DSPE-PEG2000-Mal-Cys-penetratin combines the membrane compatibility of lipids, the ability to undergo specific Michael addition reactions with thiol-containing (-SH) biomolecules (such as peptides, antibodies, and aptamers), and the ability to penetrate cell membranes, making it suitable for research on biomaterial construction and drug delivery to cells.
|
-
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
-
- HY-172272A
-
|
|
Liposome
VEGFR
|
Cancer
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
-
- HY-172503
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
-
- HY-172270A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
-
- HY-172274A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG2000-APRPG can be used for drug delivery .
|
-
-
- HY-172271A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells .
|
-
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-144004
-
|
DSPE-PEG2000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[Maleimide(polyethylene glycol)-2000] ammonium
|
Biochemical Assay Reagents
|
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
- HY-172279A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-TAT is a cell-penetrating peptide-modified PEGylated phospholipid conjugate and cellular uptake enhancer. DSPE-PEG2000-TAT forms via conjugation of Cys-TAT to DSPE-PEG2000-Mal. DSPE-PEG2000-TAT enhances liposomal cellular uptake and siRNA transfection efficiency in glomerular mesangial and macrophage cells. DSPE-PEG2000-TAT can be used for drug delivery .
|
-
- HY-172699
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .
|
-
- HY-172273A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
|
-
- HY-172500
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG2000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.
|
-
- HY-179677
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-Mal-Cys-DT7 is a phospholipid-PEG conjugate. DSPE-PEG2000-Mal-Cys-DT7 utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles.
|
-
- HY-172497
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
-
- HY-172276A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
- HY-172272A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172503
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
- HY-172270A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172274A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG2000-APRPG can be used for drug delivery .
|
-
- HY-172271A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P3252AS
-
|
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-144004
-
|
DSPE-PEG2000 Maleimide ammonium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[Maleimide(polyethylene glycol)-2000] ammonium
|
|
Pegylated Lipids
|
|
DSPE-PEG-Maleimide has DSPE phospholipid and maleimide to prepare nanostructured lipid carrier. DSPE-PEG-Maleimide extends blood circulation time and higher stability for encapsulated agents .
|
-
- HY-172279A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-TAT is a cell-penetrating peptide-modified PEGylated phospholipid conjugate and cellular uptake enhancer. DSPE-PEG2000-TAT forms via conjugation of Cys-TAT to DSPE-PEG2000-Mal. DSPE-PEG2000-TAT enhances liposomal cellular uptake and siRNA transfection efficiency in glomerular mesangial and macrophage cells. DSPE-PEG2000-TAT can be used for drug delivery .
|
-
- HY-172699
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-ANG is a conjugate of DSPE-PEG2000-MAL and Angiopep-2. Angiopep-2 is a peptide ligand that targets LRP-1. DSPE-PEG2000-ANG is used to synthesize gadolinium-boron bifunctionalized lipid nanoparticles BPA-F&DOTA-Gd@LIPO-ANG with blood-brain barrier and glioma targeting properties .
|
-
- HY-172273A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY is a PEG compound which composed of DSPE and a M2-polarized macrophages targeting peptide (M2pep, YEQDPWGVKWWY). M2pep is conjugated to a proapoptotic peptide as monovalent or multivalent ligands to concentrate the toxic effect of the peptide to M2 macrophages. DSPE-PEG2000-Mal-Cys-YEQDPWGVKWWY can be used for drug delivery .
|
-
- HY-172500
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG2000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.
|
-
- HY-179677
-
|
|
|
Pegylated Lipids
Fluorescent Lipids
|
|
DSPE-PEG2000-Mal-Cys-DT7 is a phospholipid-PEG conjugate. DSPE-PEG2000-Mal-Cys-DT7 utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles.
|
-
- HY-172497
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .
|
-
- HY-172276A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
|
-
- HY-172272A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-A7R is a PEG compound which composed of DSPE and a tumor vascular targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors .
|
-
- HY-172503
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
- HY-172270A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-PTP is synthesised by conjugating the amino group of plectin-1 peptide (PTP) with DSPE-PEG-NHS ester via amide bonds. DSPE-PEG1000-PTP can be used to construct drug delivery vectors .
|
-
- HY-172274A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-APRPG is a PEG compound which composed of DSPE and a APRPG peptide. DSPE-PEG2000-APRPG can be used for drug delivery .
|
-
- HY-172271A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
